EPIX Live signals | Maximize Profits with Getagraph.com

BUY 95096 min ago

@ $9.53

Issued: 12 Feb 2024 @ 12:36

Return: -29.07%

Previous signal: Feb 8 - 15:49

Previous signal: Sell

Return: -9.50 %

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 14:27):

Stats
Today's Volume	22 153.00
Average Volume	136 845
Market Cap	299.05M
EPS	$0 ( 2024-02-13 )
Next earnings date	( $-0.190 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-11.46
ATR14	$0.0980 (1.45%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-05	Virsik Peter	Sell	694	Common Shares
2024-03-25	Zweifach Sanford S	Buy	50 000	Options
2024-03-25	Thorell Marella	Buy	50 000	Options
2024-03-25	Sollis Gary	Buy	50 000	Options
2024-03-25	Requadt Scott	Buy	50 000	Options

INSIDER POWER
74.98
Last 100 transactions
Buy: 6 893 554 \| Sell: 774 650

Volume Correlation

Long: -0.10 (neutral)

Short: 0.30 (neutral)

Signal:(39.469) Neutral

ESSA Pharma Inc Correlation

10 Most Positive Correlations
GOODM	0.808

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ESSA Pharma Inc Correlation - Currency/Commodity

0.05
( neutral )

-0.70
( moderate negative )

0.00
( neutral )

0.64
( weak )

-0.42
( neutral )

-0.24
( neutral )

ESSA Pharma Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-118 491 (0.00 %)
EPS:	$-0.600

Q4	2023
Revenue:	$0
Gross Profit:	$-27 149.00 (0.00 %)
EPS:	$-0.120

Q3	2023
Revenue:	$0
Gross Profit:	$-30 447.00 (0.00 %)
EPS:	$-0.170

Q2	2023
Revenue:	$0
Gross Profit:	$-30 447.00 (0.00 %)
EPS:	$-0.160

Financial Reports:

No articles found.

ESSA Pharma Inc

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.